| Vinblastine | US FDA | Mycosis Fungoides | Mycosis fungoides (advanced stages) | approved | Apr 29, 1987 | openfda |
| Vorasidenib | US FDA | Grade 2 Follicular Lymphoma | VORANIGO is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection [see Dosage and Administration (2.1) , Clinical Pharmacology (12.1) and Clinical Studies (14) ]. VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection. ( 1 ) | approved | Aug 6, 2024 | openfda |
| Vorinostat | US FDA | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | ZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. ( 1 ) | approved | Oct 6, 2006 | openfda |
| Zanubrutinib | US FDA | Marginal Zone Lymphoma | Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Waldenstrom Macroglobulinemia | This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM).accelerated | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Mantle Cell Lymphoma | Mantle cell lymphoma (MCL) who have received at least one prior therapy. | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Follicular Lymphoma | Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Marginal Zone Lymphoma | Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Waldenstrom Macroglobulinemia | This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM).accelerated | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Mantle Cell Lymphoma | Mantle cell lymphoma (MCL) who have received at least one prior therapy. | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Follicular Lymphoma | Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Mantle Cell Lymphoma | Mantle cell lymphoma (MCL) who have received at least one prior therapy. | approved | Nov 14, 2019 | openfda |
| Zanubrutinib | US FDA | Follicular Lymphoma | Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. | approved | Nov 14, 2019 | openfda |
| Zanubrutinib | US FDA | Marginal Zone Lymphoma | Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. | approved | Nov 14, 2019 | openfda |
| Zanubrutinib | US FDA | Waldenstrom Macroglobulinemia | This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM).accelerated | approved | Nov 14, 2019 | openfda |